【金斯瑞生物科技(01548.HK)发布2024年度业绩,股东应占利润29.62亿美元】金斯瑞生物科技(01548.HK)发布截至2024年12月31日止年度业绩,持续经营业务的收益约为5.945亿美元,同比增加6.1%;母公司拥有人应占利润29.62亿美元,上年同期亏损9547.7万美元;每股基本利润139.63美分。

金融界
12 Mar
金斯瑞生物科技(01548.HK)发布截至2024年12月31日止年度业绩,持续经营业务的收益约为5.945亿美元,同比增加6.1%;母公司拥有人应占利润29.62亿美元,上年同期亏损9547.7万美元;每股基本利润139.63美分。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10